Abstract:Phage-derived therapies comprise phage therapy and the use of phage-derived proteins as anti-bacterial therapy. Bacteriophages are natural viruses that target specific bacteria. They were proposed to be used to treat bacterial infections in the 1920s, before the discovery and widespread over-commercialized use of antibiotics. Phage therapy was totally abandoned in Western countries, whereas it is still used in Poland, Georgia and Russia. We review here the history of phage therapy by focusing on bone and joint infection, and on the development of phage therapy in France in this indication. We discuss the rationale of its use in bacterial infection and show the feasibility of phage therapy in the 2020s, based on several patients with complex bone and joint infection who recently received phages as compassionate therapy. Although the status of phage therapy remains to be clarified by health care authorities, obtaining pharmaceutical-grade therapeutic phages (i.e., following good manufacturing practice guidelines or being “GMP-like”) targeting bacterial species of concern is essential. Moreover, multidisciplinary clinical expertise has to determine what could be the relevant indications to perform clinical trials. Finally “phage therapy 2.0” has to integrate the following steps: (i) follow the status of phage therapy, that is not settled and defined; (ii) develop in each country a close relationship with the national health care authority; (iii) develop industrial–academic partnerships; (iv) create academic reference centers; (v) identify relevant clinical indications; (vi) use GMP/GMP-like phages with guaranteed quality bioproduction; (vii) start as salvage therapy; (vii) combine with antibiotics and adequate surgery; and (viii) perform clinical trials, to finally (ix) demonstrate in which clinical settings phage therapy provides benefit. Phage-derived proteins such as peptidoglycan hydrolases, polysaccharide depolymerases or lysins are enzymes that also have anti-biofilm activity. In contrast to phages, their development has to follow the classical process of medicinal products. Phage therapy and phage-derived products also have a huge potential to treat biofilm-associated bacterial diseases, and this is of crucial importance in the worldwide spread of antimicrobial resistance.

Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections

Phage therapy: A targeted approach to overcoming antibiotic resistance

The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review

Phage Therapy: A Different Approach to Fight Bacterial Infections

The Safety and Efficacy of Phage Therapy for Bone and Joint Infections: A Systematic Review

From forgotten cure to modern medicine: The resurgence of bacteriophage therapy

Current status of bacteriophage therapy for severe bacterial infections

Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery

Phage therapy: A novel approach against multidrug-resistant pathogens

Bacteriophage therapy in musculoskeletal infections: from basic science to clinical application

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens

Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens

Phage therapy: an alternative treatment modality for MDR bacterial infections

Current Knowledge and Perspectives of Phage Therapy for Combating Refractory Wound Infections

The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections

Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future

Optimized Dosing and Delivery of Bacteriophage Therapy for Wound Infections

Phage therapy: breathing new tactics into lower respiratory tract infection treatments

Engineered bacteriophages: A panacea against pathogenic and drug resistant bacteria

Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection

Phage Therapy for Bone and Joint Infections: A Comprehensive Exploration of Challenges, Dynamics, and Therapeutic Prospects